Croma-Pharma GmbH clinical trials
The registry lists 26 studies whose lead sponsor is Croma-Pharma GmbH. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 12, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 26studies on the registry
- 2open to participants now
- 1reach primary completion within a year
Get an email when these change. Save the Croma-Pharma GmbH studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
What it is testing
The drugs Croma-Pharma GmbH’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- botulinum toxin type A3 in phase 30 open · 3
Coming up
1 of Croma-Pharma GmbH’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- 1OOct
- NNov
The study
- Oct 2027Revitalis - Midface (Cheek Area)NCT07931482
Add it to your calendar (.ics) → With an account.
What changed recently
From the registry's own updates since Oct 19, 2026.
Newly registered2
- Revitalis - Midface (Cheek Area)Nov 12, 2026NCT07931482
- Post-Approval Study of Saypha® ChIQ™ for Midface Augmentation in Subjects With Fitzpatrick Skin Types V and VINov 5, 2026NCT07918443
All 26 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 12
- 13
- 14
- 15
- 516
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 226
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Croma-Pharma GmbH.
- Croma-Pharma GmbH26 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 26 of 26.
- Revitalis - Midface (Cheek Area)RecruitingNCT07931482Not applicable
- Post-Approval Study of Saypha® ChIQ™ for Midface Augmentation in Subjects With Fitzpatrick Skin Types V and VINot yet recruitingNCT07918443Not applicable
- Filler Post Market Survey (FIPS)Active, not recruitingNCT07475455
- A Non-Interventional PMCF Study Evaluating Croma Revitalis for the Correction of Fine LinesCompletedNCT07492277
- Saypha® VOLUME Lidocaine for Midface AugmentationCompletedNCT05386030Phase 3
- Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)CompletedNCT03985982Phase 3
- Princess® VOLUME Lidocaine for the Correction of Nasolabial FoldsCompletedNCT03050710Not applicable
- Saypha® Volume LIdocaine in Nasolabial FoldsCompletedNCT04883632Not applicable
- Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study IICompletedNCT02677805Phase 3
- Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study ICompletedNCT02677298Phase 3
- Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown LinesCompletedNCT04763265Phase 2
- Post Market Study Evaluating Princess Filler Lidocaine for the Correction of Nasolabial FoldsCompletedNCT03611491Not applicable
- Study to Evaluate the Effectiveness, Safety and Long Term Safety of Saypha® FILLER Lidocaine for Lip AugmentationCompletedNCT04917588Not applicable
- Study for the Evaluation of the Efficacy and Safety of the Dermal Filler Princess® VOLUME in Nasolabial FoldsCompletedNCT01798498Not applicable
- Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF)CompletedNCT03990883Not applicable
- THIODERM ELATE for Augmentation of Very Thin, Thin, and Moderately Thick LipsCompletedNCT06135337Not applicable
- THIODERM STRONG Compared to Juvéderm® VOLUMA® Lidocaine for the Treatment of Midface Volume DeficitCompletedNCT06128109Not applicable
- THIODERM ELATE for Volume Augmentation in LipsWithdrawnNCT06133153Not applicable
- A 52-week Clinical Investigation of Princess® VOLUME PLUS Lidocaine in Subjects With Midface Volume DeficitCompletedNCT03532126
- Princess® RICH for the Correction of Fine LinesCompletedNCT03923634Not applicable
- Study of Etacoat in Patients With Cataract Surgery Via the Anterior ChamberCompletedNCT03644875
- Study of Etafill in Patients With Cataract Surgery Via the Anterior ChamberCompletedNCT03644862
- Safety and Effectiveness of THIODERM STRONG in the Correction of Nasolabial FoldsCompletedNCT03650218Not applicable
- Safety and Performance of Princess® FILLER for the Treatment of Facial Lipoatrophy, Asymmetry or ScarsCompletedNCT03050723Not applicable
- Safety and Performance of Princess® VOLUME for the Treatment of Facial Lipoatrophy, Asymmetry or ScarsCompletedNCT03050749Not applicable
- Safety of Hyaluronan Thiomer i.o. Implant During Combined Phacoemulsification - Non Penetrating Deep SclerectomyCompletedNCT01887873Phase 1